NIFTY 50 TOP GAINERS
TECHNICAL ANALYSIS STOCK
After making a marginal consolidation, Cadila Healthcare may be give a breakout from doublepattern above Rs 410-415 levels. Volumes during this price action were almost double to its average daily volumes, indicating strong buying interest after this breakout. The Relative strength index (RSI) is making the higher bottom and higher top and MACD is trading with a positive crossover. Traders can buy CADILA healthcare around current level Rs 400-406 with a stop loss below Rs 380 (closing) for target of Rs 425 -440.
Drug firm Cadila has received approval from the US health
regulator to market Tadalafil tablets, used to erectile dysfunction, in the
American market. The company has received tentative approval from the US Food
and Drug Administration (USFDA) to market the drug in strengths of 2.5 mg, 5
mg, 10 mg and 20 mg, Cadila said in a regulatory filing.
For 2 Days Free Trial Click here: Capitalheight.
No comments:
Post a Comment